Legal Actions, Quarterly Dividends, Collaborations, and New Appointments - Research Report on Johnson & Johnson, Zoetis, Abbott,

  Legal Actions, Quarterly Dividends, Collaborations, and New Appointments -
 Research Report on Johnson & Johnson, Zoetis, Abbott, Teva Pharmaceuticals,
                                  and Baxter

PR Newswire

NEW YORK, September 19, 2013

NEW YORK, September 19, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Johnson &
Johnson (NYSE: JNJ), Zoetis Inc. (NYSE: ZTS), Abbott Laboratories (NYSE: ABT),
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), and Baxter International
Inc. (NYSE: BAX). Today's readers may access these reports free of charge -
including full price targets, industry analysis and analyst ratings - via the
links below.

Johnson & Johnson Research Report

On September 12, 2013, Bloomberg reported that Johnson & Johnson (J&J) sued a
unit of Boehringer Ingelheim Gmbh (Boehringer) over whether a dispute about an
agreement to produce the cancer drug Doxil must be submitted to arbitration or
not. The report stated that lawyers for New Brunswick, New Jersey-based J&J
contend that executives of Boeringher's U.S. unit violated a 2009 agreement to
produce Doxil and left J&J struggling to meet the demand. According to the
release, J&J's Alza Corp. unit had hired Boehringer as its "sole-source
manufacturer" of Doxil in 1995; however the production halted in 2011 when a
Boehringer plant in Ohio was found to have quality issues by the U.S. FDA. As
per the Bloomberg report, J&J officials are asking Delaware Chancery Judge Leo
Strine to order Boehringer to honor its agreement to submit disputes over
Doxil production to an arbitrator. The Full Research Report on Johnson &
Johnson - including full detailed breakdown, analyst ratings and price targets
- is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/07a8_JNJ]

--

Zoetis Inc. Research Report

On September 12, 2013, Zoetis Inc.' (Zoetis) Board of Directors declared its
Q4 2013 dividend of c.$0.07 per share payable to holders of the Company's
common stock. As per Zoetis, stockholders of record on November 1, 2013 will
be paid the dividends on December 2, 2013. The Full Research Report on Zoetis
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.analystscorner.com/r/full_research_report/7e25_ZTS]

--

Abbott Laboratories Research Report

On September 12, 2013, Abbot Laboratories' (Abbott) Board of Directors
declared a quarterly common dividend of $0.14 per share. As per Abott, the
cash dividend will be payable on November 15, 2013 to shareholders of record
at the close of business on October 15, 2013. Further, Abott stated this marks
the 359th consecutive quarterly dividend to be paid by the Company since 1924.
The Full Research Report on Abbott Laboratories - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.analystscorner.com/r/full_research_report/05c1_ABT]

--

Teva Pharmaceutical Industries Ltd. Research Report

On September 16, 2013, Teva Pharmaceutical Industries Ltd (Teva
Pharmaceuticals) announced a multi-project alliance agreement with Cancer
Research Technology Ltd. (CRT) which is Cancer Research UK's technology
development arm. According to the Company, the alliance has been formed to
research and develop first-in-class cancer drugs that modulate DNA damage and
repair response (DDR) processes in cancer cells. Commenting on the
partnership, Dr. Michael Hayden, President, Teva Global R&D and Chief
Scientific Officer, stated, "For cancer patients, it is important that we
maintain the momentum of progress that has been made in oncology in recent
years. Cancer Research UK, CRT, and their outstanding academic partners, are a
driving force in the improved understanding of cancer and its treatment. This
research collaboration will build on our understanding of how cells repair DNA
damage, help us identify possible points of therapeutic intervention, and lead
us onto a pathway toward improve clinical outcomes for cancer patients." The
Full Research Report on Teva Pharmaceutical Industries Ltd. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/e3a3_TEVA]

--

Baxter International Inc. Research Report

On September 9, 2013, Baxter International Inc. (Baxter) announced the
election of Todd S. Young by its Board of Directors as the Treasurer and
Corporate Officer of the Company. Baxter informed that Young succeeds James K.
Saccaro and will report to Baxter's CFO, Robert Hombach. According to the
Company, Young joined Baxter in 2001 as corporate tax counsel, and over the
years assumed positions of increasing responsibility, and prior to joining the
new role, he served as Vice President, International Finance for the Company.
The Full Research Report on Baxter International Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.analystscorner.com/r/full_research_report/163d_BAX]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://AnalystsCorner.com



SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.